JIC
ORMP icon

Joel Isaacson & Co’s Oramed Pharmaceuticals ORMP Stock Holding History

Joel Isaacson & Co’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-700
Closed -$4K – 425
2016
Q4 		$4K Hold
700
– – ﹤0.01% 576
2016
Q3 		$5K Hold
700
– – ﹤0.01% 621
2016
Q2 		$6K Hold
700
– – ﹤0.01% 598
2016
Q1 		$5K Buy
+700
New +$4.69K ﹤0.01% 656

Other funds holding ORMP

Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Joel Isaacson & Co's ORMP Position: Q1 2017 in Review

Joel Isaacson & Co sold out of Oramed Pharmaceuticals (ORMP) in Q1 2017, closing a stake of 700 shares — an estimated $4K sold.

Joel Isaacson & Co first reported a position in ORMP in Q1 2016 and held it in 4 quarters. The position peaked at $6K in Q2 2016. 21 funds tracked by Wall St. Rank hold ORMP as of Q1 2017.

  • Joel Isaacson & Co reported no remaining Oramed Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Joel Isaacson & Co sold 700 Oramed Pharmaceuticals shares in Q1 2017, an estimated $4K.
  • Joel Isaacson & Co first reported a position in Oramed Pharmaceuticals in Q1 2016 and held it in 4 quarters.
  • Joel Isaacson & Co's Oramed Pharmaceuticals position peaked at $6K in Q2 2016.
  • 21 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2017.

Based on Joel Isaacson & Co's 13F filing for Q1 2017, filed 5 May 2017.